An ionizable lipid toolbox for RNA

Purpose: RNA therapeutics—ASOs, siRNAs, miRNAs, mRNAs, and CRISPR-Cas9 sgRNAs—are limited by nuclease degradation, large size, and negative charge. Ionisable lipids are the key LNP component that condenses RNA, enables endosomal escape, and reduces toxicity. Since 2008, many ionisable lipids have been created, but the field lacks systematic categorisation to guide next-generation design.

Hypothesis: The authors’ framing thesis: if ionisable lipids are categorised by structural class and designed with favourable features—such as degradable backbones, branched or multi-tails, appropriate pKa, and optional targeting/immunomodulatory functions—then RNA delivery potency, safety, and organ selectivity can be improved for diverse therapeutic applications.

Aims: Explain the need for ionisable lipids and the mechanism of endosomal escape. - Categorise the five major ionisable lipid types used for RNA delivery: unsaturated, multi-tail, polymeric, biodegradable, and branched-tail. - Highlight representative structures, structure–activity relationships, and key preclinical/clinical examples. - Discuss clinical development, remaining challenges, and future directions for ionisable lipid design.

Delivery system: LNP components: ionisable lipid, phospholipid, cholesterol, PEGylated lipid. - Ionisable lipid function: positively charged at acidic pH to condense RNA; neutral at physiological pH to minimise toxicity; protonated in acidic endosomes; interacts with anionic endosomal phospholipids to form cone-shaped ion pairs; drives bilayer-to-inverted hexagonal HII phase transition; facilitates membrane fusion/disruption, endosomal escape, and cytosolic cargo release. - RNA payloads: ASOs, siRNAs, miRNAs, mRNAs, sgRNAs/CRISPR-Cas9. - Five ionisable lipid classes: - Unsaturated: DLin-MC3-DMA (MC3), A6, OF-02, A18-Iso5-2DC18. - Multi-tail: 98N12-5, C12-200, cKK-E12, 9A1P9. - Polymeric: 7C1, G0-C14. - Biodegradable: L319, 304O13/3040a, 306-O12B, OF-Deg-Lin. - Branched-tail: 306O10, FTT5. - Targeting/functionalization: neurotransmitter-derived ionisable lipid for BBB crossing; other targeting strategies mentioned as future direction.

Approach: Comment/Perspective synthesising preclinical and clinical literature. Cited models include mice, non-human primates, human clinical trials, COVID-19 mRNA vaccine trials, and hATTR patients receiving CRISPR-Cas9 LNPs. As a comment article, it reports no primary experimental groups, n values, doses, or controls.

Key methods: No primary methods. The article discusses data from cited studies using: - High-throughput/combinatorial ionisable lipid synthesis and screening. - LNP formulation optimisation, including design-of-experiment methods. - In vivo gene silencing, mRNA expression, and CRISPR-Cas9 genome editing. - Biodistribution and organ-selective transfection. - Clinical trial readouts for safety, tolerability, and efficacy. - Structure–activity relationship analysis of lipid tails, linkers, pKa, and branching.

Key results: MC3 is used in the FDA-approved siRNA drug Onpattro (patisiran) for hereditary transthyretin amyloidosis. - Optimised C12-200 formulation increased mRNA expression 7-fold vs standard formulation. - 7C1 achieved ~80% endothelial gene knockdown in lungs in non-human primates without significant toxicity. - 3040a had similar potency to non-degradable C12-200 but much lower toxicity at high doses. - OF-Deg-Lin induced >85% of total protein expression in the spleen and selectively transfected splenic lymphocytes. - 306-O12B outperformed MC3 in CRISPR-Cas9 liver genome editing of Angptl3, with negligible toxicity or off-target mutagenesis. - 306O10 co-delivered multiple RNA constructs and transfected >80% of hepatocytes, Kupffer cells, and endothelial cells. - LP000001 LNP CRISPR-Cas9: a single dose led to 87% reduction of serum TTR in hATTR patients, with few or mild adverse events. - COVID-19 mRNA vaccines mRNA-1273 and BNT162b2 showed protection efficacies >94%. - Clinically advanced ionisable lipids share ester-based biodegradable structures; next most common features are multi/branched tails and unsaturation. Multi/branched-tail clinical lipids typically possess only one tertiary amine. - Challenges: acute immune responses, long-term toxicity, need for premedication with glucocorticoids/antihistamines, laborious synthesis (MC3 requires four synthetic steps and one week), and poor extrahepatic delivery—neutral LNPs mainly localise to liver.

Interpretation: The authors conclude that ionisable lipids are central to RNA therapeutic success. They argue that degradable backbones and increased branching/tail number are among the most favourable structural properties for future ionisable lipids. Next-generation lipids with additional functionalities—such as targeting and immunomodulation—will be important for specific applications. They see vast opportunities for ionisable lipid optimisation and innovation to enable broader translation of RNA therapeutics and vaccines.

Limitations: Comment/Perspective article; no primary experimental data, systematic review, or meta-analysis. - Many clinical ionisable lipid structures are not publicly disclosed; probable structures are inferred from patents and literature. - Clinical data are limited and early-stage for most RNA therapeutics beyond COVID-19 vaccines and Onpattro. - Persistent challenges include acute immune responses, long-term toxicity, scalable synthesis, and extrahepatic/organ-selective delivery. - Structure–organ selectivity relationships remain incompletely understood. - Long-term safety, repeated dosing, and broader disease applications require further investigation.